Testing a new injection for Parkinson's disease
Part of Brain & nervous system clinical trials.
This trial tests an injection called XS411CN for people with Parkinson's disease whose current medications are not working as well as before. The goal is to see if it is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 50 and 75 years old
- Have had Parkinson's disease for at least 5 years
- Experience at least 2.5 hours of 'off' time (when symptoms return) each day
- Have tried Parkinson's medications that helped before but no longer work well
- Be willing to have all recommended vaccinations up to date
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether an “autologous” (from your own body) iNSC-DAP stem-cell treatment is safe and may help symptoms in Parkinson’s disease. It is designed mainly to check safety, while also watching for signs of improvement.
This trial tests a new injection called UX-DA003 for people with Parkinson's disease whose current medications are becoming less effective. It aims to see if this treatment can help reduce "off" time and improve motor symptoms.
This trial uses special stem cells (made from skin or blood cells) to replace damaged brain cells in people with Parkinson's. The goal is to see if these cells can improve movement and reduce symptoms.
This trial tests a new cell therapy, NouvNeu001, for people with Parkinson's disease who have had symptoms for at least 4 years and are having trouble with their current medications. The goal is to see if this treatment is safe and can improve motor symptoms that are not well controlled.
This trial tests a new cell therapy called NouvNeu001 for Parkinson's disease. It involves a one-time brain surgery to deliver the treatment, and researchers will check if it's safe and helps with symptoms.
This trial tests a new treatment called XS411 for people with early-onset Parkinson's disease (age 50 or younger at diagnosis). It is for those whose motor symptoms are not well controlled with standard medications and who may benefit from a neurosurgical procedure.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.